Aptamer Group plc, a developer of novel Optimer binders to enable innovation in the life sciences industry, has opened its new facilities in York Science Park, UK, to meet increasing demand for Optimer technology.
 
Aptamer’s new facilities have tripled the Group’s previous footprint and include new containment level 1 and 2 labs. This site will help to expand the capacity of Aptamer’s Optimer platform to deliver novel binders for the bioprocessing, diagnostic, and drug development sectors. In addition to Optimer discovery and development, a portion of the new lab space will be dedicated to validation and assay development.
 
Optimer binders are next-generation aptamers that can be used as synthetic antibody alternatives. They offer key benefits of smaller size, reduced immunogenicity, increased stability, and ethical compliance as their discovery, development, and manufacture are animal-free. These binders are enabling researchers to pursue new targets and applications, such as targeted drug delivery, that have previously proven intractable with protein-based technologies.
 
“We are excited to move to the new purpose-developed site for Aptamer Group, which will enable us to keep up with the increased demand for our Optimer technology at our new larger lab and office facilities,” said, Dr. Arron Tolley, Chief Executive Officer of Aptamer Group.